We propose to develop a highly sensitive and rapid point-of-care nucleic acid test based on IQuum's lab-in-a-tube (Liat"") platform for the diagnosis of patients with dengue fever or dengue hemorrhagic fever from whole blood samples. The Liat Dengue Assay will utilize the Liat Analyzer to enable the minimally trained personnel to perform the dengue infection test at a hospital, clinic or physician's office in less than 1 hour. By enabling effective and sensitive dengue infection testing, we expect that the Liat assay will allow clinicians to quickly diagnose patients with dengue fever or dengue hemorrhagic fever and initiate appropriate treatments. The Liat Dengue Assay overcomes the limitations of current dengue infection tests, whose long turnaround time and technical complexity requires testing to be performed in centralized laboratories, resulting in missed opportunities for disease treatment or the continued use of ineffective treatment regimens. The assay will also be among the first near patient nucleic acid tests, and will provide significant benefit to patient health and welfare, as well as enhance the preparedness for this emerging disease. In Phase I, we propose to transfer the Liat Dengue Assay to manufacturing and perform analytical sensitivity and specificity studies. In Phase II, we propose to complete the analytical studies, develop and validate manufacturing processes for the Liat Dengue Assay, and conduct clinical sample study to validate the assay. At the conclusion of the pre-clinical and analytical studies, we will submit a pre-investigational device exemption (pre-IDE) to the FDA in preparation for expanded clinical study of the Liat Dengue Assay for 510(K) market clearance. , ,
Public Health Relevance: By enabling effective and sensitive dengue infection testing, the Liat"" Dengue Assay will allow clinicians to quickly diagnose patients with dengue fever or dengue hemorrhagic fever. The Liat Dengue Assay overcomes the limitations of current dengue infection tests, whose long turnaround time and technical complexity requires testing to be performed in centralized laboratories, resulting in missed opportunities for disease treatment or the continued use of ineffective treatment regimens. The assay will also be among the first near patient nucleic acid tests, and will provide significant benefit to patient health and welfare, as well as to enhance the preparedness for this emerging disease.
Thesaurus Terms: Abscission;Acute;Algorithms;American;Armed Forces Personnel;Assay;Bioassay;Biologic Assays;Biological Assay;Blood Sample;Blood Specimen;Breakbone Fever Virus;Cdc;Capital;Centers For Disease Control;Centers For Disease Control (U.S.);Centers For Disease Control And Prevention;Centers For Disease Control And Prevention (U.S.);Clinic;Clinical;Clinical Evaluation;Clinical Research;Clinical Study;Clinical Testing;Clinics And Hospitals;Clinics Or Hospitals;Collaborations;Communication, Personal;Conflict;Conflict (Psychology);Dengue;Dengue Fever;Dengue Hemorrhagic Fever;Dengue Virus;Detection;Development;Devices;Diagnosis;Diagnostic;Diagnostic Method;Diagnostic Procedure;Diagnostic Technique;Diagnostic Tests;Disease;Disorder;Distress;Doctor Of Philosophy;Dose;Economics;Emergencies;Emergency Situation;Excision;Extirpation;Figs;Figs - Dietary;Gene Products, Rna;Grant;Hcv Infection;Hosp;Head;Health;Hemorrhagic Fevers, Viral;Hepatitis C;Hepatitis C Virus Infection;Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted;Hospital Information Systems;Hospitals;Hour;Human;Human Resources;Human, General;In Vitro;Incidence;Infection;Insect Vectors;Interpersonal Communication;Laboratories;Laboratory Markers;Lead;Licensing;Life;Man (Taxonomy);Man, Modern;Manpower;Marketing;Mexico;Military;Military Personnel;Molecular;Molecular Marker Of Prognosis;Nanbh;Nat;Nih;Names;National Institutes Of Health;National Institutes Of Health (U.S.);Nucleic Acid Amplification Tests;Nucleic Acid Testing;Nucleic Acids;Pcr;Pt-Nanbh;Parenterally-Transmitted Non-A, Non-B Hepatitis;Patients;Pb Element;Performance;Personal Communication;Ph.D.;Phd;Phase;Physicians' Offices;Polymerase Chain Reaction;Poverty;Preparation;Preparedness;Process;Prognosis Marker;Prognostic Marker;Protocols, Treatment;Qualifying;Rgm;Rna;Rna, Non-Polyadenylated;Readiness;Reagent;Regimen;Removal;Reporting;Research Resources;Resources;Ribonucleic Acid;Risk;Rural Health;Sbir;Sbirs (R43/44);Sampling;Sampling Studies;Scanning;Sensitivity And Specificity;Serotyping;Services;Side;Small Business Innovation Research;Small Business Innovation Research Grant;Social Welfare;Surgical Removal;System;System, Loinc Axis 4;Technology;Testing;Time;Training;Transcript;Treatment Protocols;Treatment Regimen;Treatment Schedule;Tube;United States Centers For Disease Control;United States Centers For Disease Control And Prevention;United States National Institutes Of Health;Viral Diseases;Viral Hemorrhagic Fevers;Viremia;Virus;Virus Diseases;Viruses, General;Whblood;Who;Whole Blood;World Health Organization;Base;Breakbone Fever;Climate Change;Clinical Test;Commercialization;Cost;Disease/Disorder;Global Climate Change;Heavy Metal Pb;Heavy Metal Lead;Hemorrhagic Fever;Hemorrhagic Fever Virus;Hepatitis Non A Non B;Hepatitis Nona Nonb;Improved;Inhibitor;Inhibitor/Antagonist;Instrument;Manufacturing Process;Meetings;Non A Non B Hepatitis;Non A, Non B Hepatitis;Non-A Non-B Hepatitis;Non-A, Non-B Hepatitis;Novel;Nucleic Acid Detection;Operation;Pandemic;Pandemic Disease;Personnel;Point Of Care;Population Migration;Pre-Clinical;Preclinical;Product Development;Public Health Relevance;Rapid Detection;Rapid Diagnosis;Research Clinical Testing;Resection;Touch Panel;Touch Screen;Touch Screen Panel;Touchscreen;Touchscreen Panel;Vector;Viraemia;Viral Infection;Viral Sepsis;Virus Infection;Virusemia;Welfare
